EDX Medical Group

EDX Medical’s chief commercial officer, Eric Vick, and Erik Jensen, regional manager UK & Nordics, caught up with Marcel van Lier from our precision oncology partners, Caris Life Sciences, at ESMO. EDX Medical is delighted to be distributing Caris’ portfolio of advanced and comprehensive molecular profiling services in the UK. Digital diagnostics have been highlighted throughout #ESMO24 and it's clear this is an increasingly important part of patient care. #ESMO24

EDX Medical Group has announced the appointment of Eric Vick as Chief Commercial Officer. The appointment follows the successful completion of several key commercial agreements which enable the Company to develop and market a range of innovative diagnostic products and services in the UK and key European countries. Eric has worked in the life sciences sector for more than 25 years, building and leading commercial business units for companies from start-ups to global leaders including GSK, Novartis, ViroPharma, Bio Products Laboratory, Ethypharm and Rosemont Pharma. As a commercial leader, Eric has a proven track record of delivering sales and profit growth by launching new products, geographic expansion, business development, and M&A. Having started his career in the US, he has expanded his remit, experience and business network across Europe, Latin America, the Middle East, Africa, and Asia-Pacific. Read more:- https://lnkd.in/eKUFWt3u

Cambridge life science company EDX Medical Group plc, part of the Sir Chris Evans stable, has signed a distribution agreement with Caris Life Sciences® , a leading US-based nextgen AI TechBio and precision medicine company. EDX Medical and Caris will collaborate on a mutually exclusive basis in the UK and Nordic countries for a minimum of three years to distribute Caris’ portfolio of advanced and comprehensive molecular profiling services for clinical and research use. Caris’ solid tumour and liquid (blood) biopsy molecular profiling services, as well as AI solutions, will be available exclusively via EDX Medical immediately in the UK, Sweden, Denmark, Norway and Finland, with additional regions and products to follow. EDX Medical CEO Dr Mike Hudson said: “We are proud to have been selected by Caris to play a key role in jointly bringing these incredibly useful cancer tumour profiling services to the UK and key areas of Europe.” Dr David Spetzler, Caris Life Sciences President, added: “This collaboration aligns with Caris’ goal of enabling clinicians worldwide to make the best individualised treatment choices for their patients and ultimately helping to improve patient outcomes.” Based at Cambridge Science Park, EDX develops innovative digital diagnostic products and services supporting personalised treatments for cancer, heart disease and infectious diseases. Sir Christopher Evans, Professor, said: “The signing of this agreement signifies a further major step forward in our strategy to provide clients with access to world-class diagnostic tools and services that can change the detection, treatment and outcome of illness for patients. “The pace of scientific advancement is such that for a patient with cancer who may only be able to provide one sample and urgently needs to start optimal treatment, reviewing their whole exome and transcriptome rather than a smaller selection of genes limited by current knowledge is clearly the most robust clinical approach. We could not wish for a better partner in this field than Caris.” Full article – https://lnkd.in/e2kWnbMq

EDX Medical Group has signed a distribution agreement with Caris Life Sciences® (Caris), a leading US-based next-generation AI TechBio and precision medicine company. Under the agreement, EDX Medical and Caris will work together on a mutually exclusive basis in the United Kingdom (UK) and Nordic countries for a minimum of three years to distribute Caris’ portfolio of advanced and comprehensive molecular profiling services for clinical and research use. Professor Sir Chris Evans, OBE, founder of EDX Medical, said: “The signing of this agreement signifies a further major step forward in our strategy to provide clients with access to world-class diagnostic tools and services that can change the detection, treatment and outcome of cancer for patients. “The pace of scientific advancement is such that for a patient with cancer who may only be able to provide one sample and urgently needs to start optimal treatment, reviewing their whole exome and transcriptome rather than a smaller selection of genes limited by current knowledge is clearly the most robust clinical approach. We could not wish for a better partner in this field than Caris.” Read more:- https://lnkd.in/e_URApEP #EDXMedical hashtag #HealthcareInnovation hashtag #PointOfCareTesting hashtag #MedicalAdvancements hashtag #diagnostics hashtag #cancerdiagnostics hashtag #cancer

EDX Medical Group has announced a further important development in its cancer testing capability in collaboration with The University of Oxford. The company has entered into an exclusive agreement with Oxford University Innovation Ltd (OUI), the company which manages Oxford University’s patent portfolio, to in-license new intellectual property developed by researchers at Oxford and Birmingham Universities through research funded by Cancer Research UK (CRUK). This will enable EDX Medical to develop a much-improved test to determine safety and dose management for individual patients receiving 5-fluorouracil (5-FU), capecitabine and related chemotherapy medications. These drugs are widely used in the first-line treatment of colorectal cancer, breast cancer and cancers of the upper gastrointestinal tract but carry serious adverse side effects for certain individuals. Read more: https://lnkd.in/e6UPNhgp #EDXMedical #HealthcareInnovation #PointOfCareTesting #MedicalAdvancements #diagnostics #cancerdiagnostics #cancer

EDX Medical Group plc, which develops innovative digital diagnostic products and services supporting personalised treatments for cancer, heart disease and infectious diseases, announces today it has signed an exclusive distribution agreement with Curesponse, to market the cResponse™ cancer assay in the UK, Sweden, Finland, Norway and Denmark. cResponse™ is a groundbreaking platform that biologically assesses how an individual patient’s living tumour tissue responds to selected medicines, identifying the most effective treatment options. It is the only clinical-grade technology providing biological response data for chemotherapy, targeted biologics, and immunotherapy drugs. https://lnkd.in/erzaj5zd #EDXMedical #HealthcareInnovation #PointOfCareTesting #MedicalAdvancements #diagnostics #cancerdiagnostics

EDX Medical is delighted to announce the forthcoming launch in the UK of new state of the art testing for identifying the risk of hereditary cancer. Comprehensive hereditary germline cancer testing is designed to accurately predict if family members of cancer patients are at increased risk from the disease. A pan-cancer test which achieves 99% sensitivity and identifies mutations in 70 genes known to be associated with cancers which have a strong inherited, genetic component, including prostate, breast, colorectal, pancreatic and ovarian cancers, will be made available to health professionals later this summer. Comprehensive hereditary germline cancer testing will enable doctors to advise family members of cancer patients on lifestyle choices and actions they can take to delay or prevent onset of the disease. Read more here: https://lnkd.in/eckgzXn7 #EDXMedical #HealthcareInnovation #PointOfCareTesting #MedicalAdvancements #diagnostics #cancerdiagnostics

EDX Medical Group is recruiting - we are now actively seeking candidates to lead the EDX Cambridge Lab quality and compliance activities, providing advice and assurance to colleagues in R&D, technical and commercial functions and senior management. Learn more: https://lnkd.in/dwe2Nqzd #EDXMedical #HealthcareInnovation #PointOfCareTesting #MedicalAdvancements #diagnostics #cancerdiagnostics #ISO15189

EDX Medical Group is recruiting - we are now actively seeking candidates for our Clinical Product Specialist roles. Click the link below for more details. #EDXMedical #HealthcareInnovation #PointOfCareTesting #MedicalAdvancements #diagnostics #cancerdiagnostics

As part of its Future Cancer Inquiry, the UK Parliament’s Health & Social Care Select Committee has taken oral evidence this week from experts to establish the extent to which innovation can improve outcomes for some of the least survivable cancers. Several speakers highlighted the need for a step-change in rapid diagnostic provision including genomic profiling and data analysis in order to ensure rapid adoption of the most effective treatments. Read more - and view excerpts from the session - on our website: https://lnkd.in/eFxyijMu #EDXMedical #HealthcareInnovation #PointOfCareTesting #MedicalAdvancements #diagnostics #cancerdiagnostics